Kornimate/medical-research-clean huggingface dataset:
cell content of sputum induced by hypertonic saline in adolescents with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: cystic fibrosis requires regular monitoring of bacterial colonization of sputum. the collection is done during scheduled consultations or urgently during exacerbations during the respiratory physiotherapy session, which is increasingly often associated with nebulization of hypertonic salt serum (ssh). this allows, compared to simple expectoration, to obtain a greater density and diversity of germs. however, no study has focused on researching the precise place of origin of the collected secretions. our aim is therefore to compare, in this pilot study in 20 adolescents suffering from cystic fibrosis and regularly followed at the pediatric crcm, the ratio between squamous cells (cm, ent origin) and broncho-alveolar cells in sputum obtained spontaneously and induced with of the ssh (collaboration with professor roll). the secondary criteria are the cm/bronchial cell ratio, the cm/alveolar macrophage ratio, cell viability and microbiological diversity. the hypothesis of this research is as follows: the nebulization of ssh before expectoration makes it possible to obtain a greater quantity of secretions from the broncho-alveolar sphere than during simple expectoration. in the cohort of 165 patients followed at the pediatric crcm of marseille, only 25 patients correspond to the inclusion criteria: they are between 12 and 17 years old, master autogenous drainage as well as spontaneous expectoration in sufficient quantity to carry out the research. they must also have been in stable clinical condition for at least one month. taking into account the non-inclusion criteria (refusal to participate, systemic antibiotic therapy, respiratory decompensation or upper airway infection, spo2 less than 92% before nebulization, appearance of hemoptysis in the last three months), the number of subjects is fixed. to 20. each patient participates in a single day of hospitalization scheduled at the pediatric crcm: at 9 a.m. simple expectoration and at 1 p.m., expectoration caused by ssh. the subject is therefore his own witness. the study inclusion period is one year.


Eligibility criteria:
inclusion criteria: * adolescent between 12 and 17 years old with definite cystic fibrosis (two cftr gene mutations identified and positive sweat test) * patient followed at the pediatric crcm of marseille * patient able to expectorate spontaneously and master autogenous drainage * patient in stable clinical condition for 1 month exclusion criteria: * patient refusing the study * patient under systemic antibiotic therapy * patient with respiratory decompensation or upper airway infection * patient with oxygen saturation \< 92% before nebulization * patient with hemoptysis in the last 3 months * patients with decompensated heart failure
combination chemotherapy or observation following surgery in treating infants with neuroblastoma

Conditions: Neuroblastoma

Summary: rationale: sometimes neuroblastoma will regress without treatment, but sometimes additional treatment may be necessary. giving more than one chemotherapy drug after surgery to remove the tumor may kill more tumor cells. purpose: phase ii trial to study combination chemotherapy or observation following surgery in treating infants with neuroblastoma.

objectives: i. determine the incidence of spontaneous regression of localized neuroblastoma in infants. ii. determine how many infants with neuroblastoma do not need chemotherapy. iii. evaluate the time course of regression by radiologic criteria and catecholamine metabolites. iv. determine the reliability of risk estimation by molecular characteristics (n-myc amplification, cd44, del 1p) compared to clinical criteria. v. evaluate whether reduced therapeutic toxicity results in a decrease in treatment-related deaths. vi. correlate cytostatic drug levels with chemotherapy side effects. outline: all patients undergo resection of the primary tumor and n-myc determination within 6 months of age, unless critically ill, then are treated according to risk. patients with amplified n-myc or with indeterminate n-myc amplification but with other risk features are treated per protocol ger-nb90. stage 4s patients who are critically ill or thrombocytopenic receive doxorubicin, vincristine, and cyclophosphamide over 7 days. patients with no amplification of n-myc are observed for 6 months (until between 12 and 18 months of age). patients with minimal residual disease (less than 10% or diameter no greater than 2-5 mm) continue observation, while those with residual disease but no disease progression undergo repeat biopsy. patients whose biopsy indicates tumor regression also continue observation. all other patients, including those with disease progression, are treated per protocol ger-nb90. projected accrual: 36-44 patients per year will be accrued (22-27 patients with stages 1-3, 8-10 patients with stage 4s, and 6-7 patients with stage 4 neuroblastoma).

Eligibility criteria:
disease characteristics: see general eligibility criteria patient characteristics: see general eligibility criteria

Keywords: localized resectable neuroblastoma regional neuroblastoma stage 4s neuroblastoma localized unresectable neuroblastoma
cannabidiol in sickle cell disease

Conditions: Sickle Cell Disease

Summary: randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

the researchers will conduct a randomized, double blind, placebo-controlled, study of cannabidiol in an oral formulation. participants will be enrolled when they are not in pain crisis and have demonstrated a urine toxicology test free from cannabinoids in the past 30 days. the sample size will be 52 participants, aged ≥18, with 1:1:1:1 allocation of placebo to 3 drug doses. this is a dose finding study with a primary outcome of reduction of inflammatory cytokine tnfα.

Eligibility criteria:
inclusion criteria: * age \>18 years * clinical diagnosis of scd (hbss, hbsc, hbsβ+; thal, hbsβ0thal, hbs variants) * baseline score of 60 or lower on the ascq-me 7-day pain interference domain * if on a scd modifying therapy (hydroxyurea, regular blood transfusions, l-glutamine, voxelotor, crizanlizumab), on stable dose for at least 3 months * if using opioids for pain at home, on stable dose for at least 3 months * one urine toxicology negative for cannabinoids within 30 days of randomization * willing to abstain from cannabis, medical and illicit, during study weeks 1 through 4 • not pregnant or nursing * if a woman capable of becoming pregnant, willing to use a medically accepted form of birth control for the duration of study participation. accepted forms include oral contraception, medroxyprogesterone, contraceptive implants or patch, surgical sterilization, total abstinence. * able to consent for research exclusion criteria: * no known intolerance to cannabinoids * no history of psychotic episode, psychosis, or active suicidality * no contraindication to epidiolex with attention to potential side effects, concurrent medications/substances, and concurrent medical problems, as evaluated by a physician * not a daily cannabis user * no diagnosis of active substance use disorder * no alt\>3 times the upper limit of normal

Keywords: chronic pain epidiolex cannabidiol
evaluation of a yoga intervention for post-traumatic stress disorder

Conditions: Post-Traumatic Stress Disorder

Summary: the main objective of this preliminary randomized controlled clinical trial is to establish efficacy and feasibility of a yoga-based treatment for ptsd in military veterans as compared to a delayed yoga treatment (waitlist control) group. secondary objectives are to evaluate ptsd characteristics that may also be improved with the treatment and acceptability and compliance with the treatment.

specific aims: 1. to evaluate the hypothesis that a 10-week yoga-based intervention will reduce ptsd severity to a statistically and clinically significant degree relative to a pretreatment baseline evaluation and to a waitlist control group. 2. to evaluate the hypothesis that ptsd patients will show improvement in regulation of physiological arousal in the autonomic nervous system relative to pretreatment. 3. to evaluate that hypothesis that symptoms associated with ptsd such as depression, anxiety, insomnia and quality of life will also be improved. 4. to evaluate the hypothesis that military veterans with ptsd can be successfully recruited into a yoga intervention study and will find the intervention acceptable and tolerable and will exhibit high compliance.

Eligibility criteria:
inclusion criteria: * male and female military veterans and active duty military personnel aged 18 and older * a dsm iv diagnosis of post-traumatic stress disorder * potential subjects on medications are eligible to participate in the study * potential subjects who receive ongoing medical or psychological treatment are eligible to participate in this study as long as these treatments do not include more than one hour weekly of relaxation and mind-body based stress reduction strategies (strategies directly related to meditation and yoga) * potential subjects are eligible to participate in this study if they have sufficient mental and physical ability to fully participate in the parameters of the study. subjects must be able to understand and comply with instructions in the group yoga sessions and home practice, complete questionnaires, participate in clinical interviews, and take part in all data collection activities. subjects with severe mental or physical concerns that may prevent them from understanding and/or complying with the treatment will be excluded. for example, potential subjects confined to wheelchairs will not be eligible, although subjects with artificial limbs who are able to reasonably participate in the intervention may be deemed eligible. these determinations will be made during discussions with potential subjects on a case by case basis during the screening process exclusion criteria: * potential subjects are ineligible if pregnant and in their third trimester. * potential subjects are ineligible if they are confined to a wheel chair.

Keywords: post traumatic stress disorder yoga meditation military veteran trauma stress depression anxiety insomnia autonomic
effect of simethicone on bowel preparation for colonoscopy

Conditions: Colorectal Cancer

Summary: optimal bowel preparation is essential for colonoscopy efficacy and safety. mucosal visualization during colonoscopy is often limited by residual stool, bubbles, bile, intraluminal fluid, and debris, which increase the risk of missing flat adenomas or other small lesions.therefore, intestinal preparation is necessary to remove residual materials prior to endoscopy. a combined agent, low-dose peg with ascorbic acid (peg-asc), is one low-volume solution commonly used in korea (coolprep®; taejoon pharmaceuticals, seoul, korea). however, practitioners have noted an increased incidence of bubble formation with this preparation method. to the investigators knowledge, no previous study has assessed colon preparation in patients administered simethicone. the purpose of this study was to compare the quality of bowel preparation and compliance between peg-asc and peg-asc with simethicone. the effectiveness of adding simethicone as an antifoaming agent to improve bowel cleansing for colonoscopy was evaluated in terms of bowel preparation scale and bubble score, and the compliance of both patients and endoscopists was also investigated using a questionnaire.

1. study design: endoscopist-blinded, prospective, randomized controlled trial 2. subjects - a single-center, randomized, observer-blinded study was performed at korea university hospital in anam. outpatients were prospectively enrolled. each group of the patients will receive peg-asc or peg-asc with simethicone before colonoscopy. 3. sampling design: consecutive recruitment of consenting patients 4. variables predictor 1. group 1 (peg-asc) received 1 l solution of peg-asc at 7 p.m the evening before colonoscopy and another 1 l solution of peg-asc at 5 hours before procedure; 2. group 2 (peg-asc with simethicone) received 1 l solution of peg-asc at 7 p.m the evening before colonoscopy and another 1 l solution of peg-asc at 5 hours before procedure;two packs (200 mg/10 ml each) of simethicone (400 mg) was mixed with last 500 ml of additional clear fluid. 5. primary outcome: quality of bowel preparation \[boston bowel preparation scale, bubble score\] 6. secondary outcome: patients and endoscopists' compliance\[tolerability, palatability of patient, fatigue score of endoscopist\]

Eligibility criteria:
inclusion criteria: * male or female patients, * aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study exclusion criteria: * patients who had chronic kidney disease, * severe heart failure(new york heart association \[nyha\] class iii or iv) * uncontrolled hypertension (systolic pressure ≥170 mm hg, diastolic pressure ≥100 mm hg) * severe constipation * any bowel resection * significant gastroparesis, or * suspected bowel obstruction or perforation.

Keywords: bowel preparation simethicone polyethylene glycol with ascorbic acid
impact of a perioperative physical exercise and respiratory physiotherapy program on the patient undergoing bariatric surgery

Conditions: Bariatric Surgery and Physical Activity; Obesity/Therapy; Bariatric Surgery Complications; Bariatric Patients

Summary: the goal of this clinical trial is to see the impact of a physical exercise programme and respiratory physiotherapy before and after bariatric surgery in obese patients. the main questions it aims to answer are: could it help to avoid decompensation of underlying diseases? could it reduce the risks associated with the intervention and the number of adverse effects during the postoperative period? could it reduce the number of patients and encourage early discharge? how does exercise affect epigenetics in obese patients undergoing bariatric surgery? can we correlate epigenectic markers obtained from tissue obtained by invasive procedures such as fat or muscle to those obtained by non-invasive methods such as blood and saliva samples? how does exercise affect the hepatic tissue in obese patients undergoing bariatric surgery? and are the any predictive markers in pre-exercise samples that can correlate with the evolution of liver diseases such asl nalfd or nash? researchers will compare one group of subjects performing the exercise programme and respiratory physiotherapy and anoher group performing the normal activities of routine clinical practice. participants, who are on the surgical waiting list for bariatric surgery, will be assigned to one of the two groups. participants in group 2 will follow the normal procedure before and after surgery. participants in group 1 will be asked to do a exercise programme and respiratory physiotherapy before and after surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing bariatric surgery at the general and digestive surgery department of the álvaro cunqueiro hospital in vigo. * be over 18 and under 69 years old. * sign the informed consent to participate in the study. exclusion criteria: * patient's refusal to enter the study. * inability to comprehend participation in a study. * urgent interventions. * patients undergoing combined surgery with another surgical service. * patients who cannot read and write or are dependent on a legal representative. * patients on treatment for diabetes with glp-1 agonists (glucagon-like peptide type 1 agonists) and/or sglt2 inhibitors (sodium-glucose cotransporter type 2 inhibitors) whose dose is not stable in the last 3 months.

Keywords: bariatric surgery obesity respiratory physiotherapy exercise programme
clinical characteristics and outcomes among stemi patients with cardiogenic shock at abu dhabi city

Conditions: ST Elevation Myocardial Infarction; Cardiogenic Shock

Summary: a retrospective study on the clinical characteristics and treatment outcomes of patients admitted with st-elevation myocardial infarction (stemi) complicated with cardiogenic shock (cs) during admission or cs development during their hospital stay for two tertiary hospitals in abu dhabi, uae, from 2020-2024.

cardiovascular disease (cvd) accounts for 40% of mortality in the uae, which is higher than the global average. long-term trends, incidence studies, and best practice guidance on cardiogenic shock (cs) with st-elevation myocardial infarction (stemi) in the united arab emirates (uae) and the gulf cooperation council (gcc) are limited. through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in sheikh khalifa medical city (skmc) and sheikh shakhbout medical city (ssmc) tertiary hospitals for patients admitted with stemi and cs or developed cs after hospitalization with stemi during january 2020-january 2024.\[200-400 participants\]. data will be collected from eligible patients' electronic medical records (emr).

Eligibility criteria:
inclusion criteria: * age more than 18. * stemi complicated by cardiogenic shock. * were hospitalized or treated at ssmc or skmc for stemi complicated by cardiogenic shock. * patient admitted between january 2019 to march 2024. exclusion criteria: * age less than 18. * shock patient not related to myocardial infarction. * nstemi-related cardiogenic shock. * patients who were not treated at ssmc or skmc for the stemi complicated by cardiogenic shock. * patient not admitted between january 2019 to march 2024.

Keywords: stemi cardiogenic shock morbidity mortality
patient-reported outcomes in adults with congenital heart disease

Conditions: Heart Defects, Congenital

Summary: the purpose of this study is to examine the differences in perceived health, psychosocial functioning, behavioral outcomes and quality of life of adults with congenital heart disease who are living in different areas of the world, and how these differences can be understood (e.g., differences in sense of coherence or illness perceptions).


Eligibility criteria:
inclusion criteria: * diagnosed with congenital heart disease, defined as: a gross structural abnormality of the heart or intra-thoracic great vessels that is actually or potentially of functional significance (including mild, moderate, and severe heart defects) * 18 years of age or older * diagnosed under the age of ten, i.e. before adolescence * continuing follow-up at an adult congenital heart disease center or included in a national/regional registry * physical, cognitive, and language abilities to complete self-report questionnaires exclusion criteria: * prior heart transplantation * isolated pulmonary hypertension * syndromes affecting cognitive abilities

Keywords: heart defects, congenital patient-reported outcomes health status factors, psychosocial health behavior quality of life sense of coherence illness perceptions depression anxiety
a phase i clinical study of recombinant humanized anti-cd20(b-lymphocyte antigen cd20) monoclonal antibody subcutaneous injection in the treatment of primary membranous nephropathy

Conditions: Primary Membranous Nephropathy

Summary: this phase i clinical study assessed the safety, tolerability, pharmacokinetic and pharmacodynamic profiles and preliminary efficacy of subcutaneous injection of recombinant humanized anti-cd20 monoclonal antibody in the treatment of primary membranous nephropathy


Eligibility criteria:
inclusion criteria: 1. subjects who have fully understood this study and voluntarily signed the informed consent form; 2. male or female subjects, aged between 18 and 75 years; 3. subjects with primary membranous nephropathy pathologically confirmed by renal biopsy; 4. subjects with systolic blood pressure ≤ 140 mmhg and diastolic blood pressure ≤ 90 mmhg at screening; 5. if taking acei(angiotensin converting enzyme inhibitors), arb(angiotensin receptor blocker), a stable dose within 4 weeks before screening is required; 6. subjects who are able to follow the study protocol as judged by the investigator. exclusion criteria: 1. subjects with secondary membranous nephropathy; 2. subjects with uncontrolled blood pressure as judged by the investigator within 3 months before screening; 3. subjects with decreases in urine protein ≥ 50% within 6 months before screening; 4. subjects who have received or are receiving renal replacement therapy; 5. subjects with type 1 diabetes mellitus, or those with type 2 diabetes mellitus who are diagnosed as diabetic nephropathy by percutaneous renal biopsy; 6. subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment; 7. subjects with active bacterial, viral, fungal, mycobacterial, parasitic or other infections requiring systemic antibiotics or antiviral therapy; 8. subjects with known history of severe allergic reactions to humanized monoclonal antibodies； 9. subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug; 10. pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug; 11. subjects with serious, progressive, or uncontrolled disease that may increase risks during the participation in the study as assessed by the investigator; 12. subjects with a history of alcoholism or drug abuse within 12 months; 13. subjects with positive hepatitis b surface antigen; those with positive hepatitis c virus antibody; those with a history of immunodeficiency; 14. subjects with cd4+ t lymphocyte count \< 300 cells/μl; 15. other conditions unsuitable for participation in this study determined by the investigator.